{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fidpodcast.simplecast.com%2Fepisodes%2Flong-acting-art-cabotegravir-plus-rilpivirine-AQaI826h","width":444,"version":"1.0","type":"rich","title":"Long-Acting ART: Cabotegravir Plus Rilpivirine","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/dc7c09c1-61de-489d-8f08-99d6a956a195/59355b92-8679-4ea1-b4e2-0f51859d11a7/cmoh-dm-prp5074-pod8-3000x3000.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/faad340b-407b-4347-93ce-9643c4198ab0\" height=\"200\" width=\"100%\" title=\"Long-Acting ART: Cabotegravir Plus Rilpivirine\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Listen to Ian Frank, MD, discuss long-acting HIV treatment with cabotegravir plus rilpivirine for treatment-experienced PWH, including efficacy data, initiation strategies, virologic failure data, and safety information."}